Improvement of urinary tract symptoms and quality of life in benign prostate hyperplasia patients

Benign prostatic hyperplasia is an enlarged prostate gland can cause uncomfortable urinary symptoms

HPN December 2021 Digital – 88, 90, 92

Benign prostatic hyperplasia (BPH) affects aging men and is the most common urologic disease among elderly men.

BPH is the consequence of the proliferation of both epithelial and stromal cells. This is from the transition zone and periurethral prostatic areas.

It typically develops after the age of 40 years, ranging in prevalence from > 50% at 60 years to as high as 90% by 85 years.

Lower urinary tract obstructive, and lower urinary tract symptoms (LUTS) drive the diagnosis of BPH. I.e. urinary hesitancy, urgency, frequency, and post-void dribble.

Pharmacological treatment possibilities include α-adrenergic antagonists or 5-α reductase inhibitors. However, one-third of patients with LUTS do not respond to either treatment approach. The occurrence of side-effects have penalized a fraction of responders.

Patients who are resistant to medical treatment, or become resistant will become candidates for surgical intervention to reduce LUTS severity.

Further understanding of the causes of LUTS will guide interventions to prevent LUTS or increase sensitivity to medical treatment.

To date, there are multiple theories on the cellular and molecular processes. Although these are underlying the pathogenesis of BPH leading to symptomatic disease.

In addition to androgens, both chronic and acute inflammation can lead to events that can cause proliferation. These are within prostatic tissue through a variety of mechanisms, notably oxidative stress.

Non-steroidal and anti-inflammatory drugs improve urinary symptoms and flow measures at present. But their long-term effectiveness and safety are not know.

Associated with each other is the centralized adipose deposition and the severity of prostate tissue inflammation and LUTS.

It was also an approach to minimize centralized fat deposition may reduce LUTS severity in BPH patients.

Widely used for the treatment of prostate diseases, phytocompounds in the form of plant portions or exacts.

In this context, a large number of anti-inflammatory compounds have been identified in tomato extracts. Moreover, tomato consumption reduces inflammation by decreasing inflammatory cytokines in overweight and obese men.

Read our latest magazine HERE

Catch up on our previous magazines HERE